-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Brokers Offer Predictions for Legend Biotech Co.'s Q1 2023 Earnings (NASDAQ:LEGN)
Brokers Offer Predictions for Legend Biotech Co.'s Q1 2023 Earnings (NASDAQ:LEGN)
Legend Biotech Co. (NASDAQ:LEGN – Get Rating) – Stock analysts at Jefferies Financial Group issued their Q1 2023 EPS estimates for shares of Legend Biotech in a research report issued on Tuesday, January 24th. Jefferies Financial Group analyst K. Shi expects that the company will post earnings of ($0.24) per share for the quarter. The consensus estimate for Legend Biotech's current full-year earnings is ($2.52) per share. Jefferies Financial Group also issued estimates for Legend Biotech's Q2 2023 earnings at ($0.33) EPS, Q3 2023 earnings at ($0.36) EPS, Q4 2023 earnings at ($0.32) EPS, FY2023 earnings at ($1.25) EPS, FY2024 earnings at ($0.45) EPS, FY2025 earnings at $1.07 EPS, FY2026 earnings at $2.35 EPS and FY2027 earnings at $4.10 EPS.
Get Legend Biotech alerts:Other analysts have also recently issued research reports about the stock. UBS Group initiated coverage on shares of Legend Biotech in a research report on Tuesday, December 6th. They set a "buy" rating and a $66.00 target price for the company. Barclays upped their price objective on shares of Legend Biotech from $53.00 to $65.00 and gave the company an "overweight" rating in a research report on Wednesday. Cowen initiated coverage on shares of Legend Biotech in a research report on Tuesday, November 1st. They issued an "outperform" rating for the company. Piper Sandler upped their price objective on shares of Legend Biotech from $72.00 to $78.00 and gave the company an "overweight" rating in a research report on Tuesday, December 20th. Finally, Guggenheim initiated coverage on shares of Legend Biotech in a research report on Monday, October 31st. They issued a "neutral" rating for the company. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $70.14.
Legend Biotech Stock Performance
Shares of Legend Biotech stock opened at $52.71 on Friday. The firm has a fifty day moving average of $51.28 and a two-hundred day moving average of $48.02. The stock has a market capitalization of $8.65 billion, a price-to-earnings ratio of -45.24 and a beta of -0.13. Legend Biotech has a 52 week low of $30.75 and a 52 week high of $57.72.Hedge Funds Weigh In On Legend Biotech
Large investors have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in Legend Biotech by 174.8% during the 2nd quarter. FMR LLC now owns 6,663,704 shares of the company's stock worth $366,505,000 after purchasing an additional 4,239,041 shares in the last quarter. Mackenzie Financial Corp increased its holdings in Legend Biotech by 33.9% during the 3rd quarter. Mackenzie Financial Corp now owns 172,049 shares of the company's stock worth $7,020,000 after purchasing an additional 43,561 shares in the last quarter. Aviva PLC boosted its stake in shares of Legend Biotech by 16.8% during the 2nd quarter. Aviva PLC now owns 23,600 shares of the company's stock worth $1,298,000 after buying an additional 3,400 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Legend Biotech by 4.7% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 102,516 shares of the company's stock worth $5,638,000 after buying an additional 4,613 shares during the last quarter. Finally, Samlyn Capital LLC acquired a new position in shares of Legend Biotech during the 2nd quarter worth about $24,970,000. Institutional investors own 38.88% of the company's stock.
About Legend Biotech
(Get Rating)
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma.
Read More
- Get a free copy of the StockNews.com research report on Legend Biotech (LEGN)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
传奇生物(纳斯达克代码:LEGN-GET Rating)-杰富瑞金融集团的股票分析师在1月24日星期二发布的一份研究报告中发布了他们对传奇生物股票2023年第一季度每股收益的估计。杰富瑞金融集团(Jefferies Financial Group)分析师K.Shih预计,该公司本季度每股收益将达到0.24美元。对新浪传奇生物目前全年收益的普遍预期为每股2.52美元。杰富瑞金融集团还发布了对传奇生物2023年第二季度每股收益的预测,2023年第三季度每股收益(0.36美元),2023年第四季度每股收益(0.32美元),2023财年每股收益(1.25美元),2024财年每股收益(0.45美元),2025财年每股收益1.07美元,2026财年每股收益2.35美元,以及2027财年每股收益4.10美元。
到达传奇生物警报:其他分析师最近也发布了关于该股的研究报告。瑞银集团在12月6日(星期二)的一份研究报告中启动了对传奇生物股票的报道。他们为该公司设定了“买入”评级和66.00美元的目标价。巴克莱周三在一份研究报告中将传奇生物的目标价从每股53.0美元上调至每股65.00美元,并给予该公司“增持”评级。考恩在11月1日星期二的一份研究报告中发起了对传奇生物股票的报道。他们对该公司的评级为“跑赢大盘”。12月20日(星期二),派珀·桑德勒在一份研究报告中将传奇生物的目标股价从72美元上调至78美元,并给予该公司“增持”评级。最后,古根海姆在10月31日(星期一)的一份研究报告中启动了对传奇生物股票的报道。他们对该公司的评级为“中性”。一名投资分析师对该股的评级为持有,九名分析师对该股的评级为买入。根据MarketBeat的数据,该股目前的平均评级为“中等买入”,平均目标价为70.14美元。
传奇生物股票表现
上周五,新浪传奇生物的股价开盘报52.71美元。该公司的50日移动均线切入位在51.28美元,200日移动均线切入位在48.02美元。该股市值为86.5亿美元,市盈率为-45.24,贝塔系数为-0.13。传奇生物的52周低点为30.75美元,52周高点为57.72美元。对冲基金在传奇生物上发表看法
大型投资者最近增持或减持了该公司的股份。FMR LLC在第二季度增持了174.8%的传奇生物股份。FMR LLC在上个季度额外购买了4,239,041股后,现在拥有6,663,704股该公司股票,价值366,505,000美元。麦肯锡金融公司在第三季度增持了33.9%的传奇生物股份。Mackenzie Financial Corp目前持有172,049股该公司股票,价值7,020,000美元,此前该公司在上个季度又购买了43,561股。英杰华在第二季度增持了16.8%的传奇生物股份。英杰华在上个季度又购买了3,400股英杰华股票,目前持有23,600股,价值1,298,000美元。三井住友信托控股有限公司(Sumitomo Mitsui Trust Holdings Inc.)在第二季度增持了4.7%的传奇生物股份。三井住友信托控股有限公司(Sumitomo Mitsui Trust Holdings Inc.)现在持有102,516股该公司股票,价值5,638,000美元,该公司在上个季度又购买了4,613股。最后,Samlyn Capital LLC在第二季度收购了价值约24,970,000美元的传奇生物新头寸。机构投资者持有该公司38.88%的股份。
关于传奇生物
(获取评级)
传奇生物是一家临床阶段的生物制药公司,通过其子公司,在美国和国际上从事肿瘤和其他适应症的新型细胞疗法的发现和开发,中国说。其主要候选产品LCAR-B38M是一种用于治疗多发性骨髓瘤(MM)的嵌合抗原受体,并与标准三联疗法治疗难治性多发性骨髓瘤进行了比较。
阅读更多内容
- 在传奇生物上免费获取斯托克新闻网的研究报告(乐高)
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升,提振销售观点
- KLA公司:在动荡不安的半市场中站稳脚跟
接受传奇生物日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对传奇生物及相关公司评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧